News
ROIV
27.83
-2.45%
-0.70
Immunovant director Robert Graham Susman sells 2,502 shares for $67,988.34
PUBT · 15h ago
UPDATE 2-Moderna tops revenue estimates on stronger international COVID vaccine sales
Reuters · 1d ago
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Reuters · 1d ago
Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy
Seeking Alpha · 2d ago
Weekly Report: what happened at ROIV last week (0420-0424)?
Weekly Report · 5d ago
SiTime, Photronics, Icici, Roivant, Marqeta Shake Markets
TipRanks · 04/25 13:01
Roivant Sciences (ROIV) Valuation Check After Recent Share Price Volatility
Simply Wall St · 04/25 10:11
Zura Bio names Marlyn Mathew principal financial, accounting officer after CFO exit
PUBT · 04/23 21:06
Top Biotech Insider Makes Bold Multi-Million Dollar Stock Move
TipRanks · 04/23 02:04
Roivant Sciences participates in a conference call with JPMorgan
TipRanks · 04/22 16:03
Europe Clears First Flu/COVID Combo Shot From Moderna
Benzinga · 04/21 17:58
Roivant Sciences Rocked by Major Insider Stock Sale from Its CEO
TipRanks · 04/21 02:02
Roivant CEO Matthew Gline disposes of 289,774 common shares for $8.45 million
PUBT · 04/20 22:27
Weekly Report: what happened at ROIV last week (0413-0417)?
Weekly Report · 04/20 09:52
Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan
TipRanks · 04/18 12:17
Roivant Sciences Price Target Raised to $40.00/Share From $22.00 by Piper Sandler
Dow Jones · 04/16 17:37
Roivant Sciences Is Maintained at Overweight by Piper Sandler
Dow Jones · 04/16 17:37
Roivant Sciences assumed with an Overweight at Piper Sandler
TipRanks · 04/16 14:07
Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)
TipRanks · 04/16 11:15
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN)
TipRanks · 04/15 11:50
More
Webull provides a variety of real-time ROIV stock news. You can receive the latest news about Roivant Sciences through multiple platforms. This information may help you make smarter investment decisions.
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.